Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The first-in-man study of CCS1477 for the treatment of Castrate resistant prostate cancer

Trial Profile

The first-in-man study of CCS1477 for the treatment of Castrate resistant prostate cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone (Primary) ; CCS 1477 (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2018 According to a CellCentric media release, this clinical trial has been initiated following regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA).
    • 25 Jun 2018 According to a CellCentric media release, status changed from planning to recruiting.
    • 25 Jun 2018 According to a CellCentric media release, this study is being led by Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top